High-dose vitamin D3 supplementation in children and young adults with HIV: A randomized, placebo-controlled trial

Journal of Pediatric Infectious Diseases

Volumn 34, Issue 2, 2015, Pages e32-e40

  Stallings, Virginia A ^a,b   Schall, Joan I ^a   Hediger, Mary L ^a   Zemel, Babette S ^a,b   Tuluc, Florin ^a,b   Dougherty, Kelly A ^a,b   Samuel, Julia L ^a   Rutstein, Richard M ^a,b  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Cholecalciferol; Nutrition; Pediatric HIV; Vitamin D3 supplementation

Indexed keywords

COLECALCIFEROL; PLACEBO; VIRUS RNA; 25 HYDROXYVITAMIN D; ANTIRETROVIRUS AGENT;

ADOLESCENT; ADULT; AFRICAN AMERICAN; ARTICLE; CHILD; CHILDHOOD DISEASE; CONTROLLED STUDY; DIETARY REFERENCE INTAKE; DOUBLE BLIND PROCEDURE; DRUG MEGADOSE; DRUG SAFETY; FEMALE; FOLLOW UP; HELPER CELL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISPANIC; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE STATUS; MAJOR CLINICAL STUDY; MALE; PERINATAL INFECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VIRUS LOAD; VITAMIN SUPPLEMENTATION; ABSENCE OF SIDE EFFECTS; DRUG EFFICACY; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; TREATMENT DURATION; VITAMIN BLOOD LEVEL; YOUNG ADULT; HIV INFECTIONS; IMMUNOLOGY; PRESCHOOL CHILD; PROCEDURES; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHILD; CHILD, PRESCHOOL; CHOLECALCIFEROL; DOUBLE-BLIND METHOD; FEMALE; HIV INFECTIONS; HUMANS; MALE; PLACEBOS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84925591917     PISSN: 13057707     EISSN: 13057693     Source Type: Journal    
DOI: 10.1097/INF.0000000000000483     Document Type: Article

References (67)

1. Viard JP, Souberbielle JC, Kirk O, et al; EuroSIDA Study Group. Vitamin D and clinical disease progression in HIV infection: results from the EuroSIDA study. AIDS. 2011;25:1305-1315.
2. Vescini F, Cozzi-Lepri A, Borderi M, et al Icona Foundation Study Group. Prevalence of hypovitaminosis D and factors associated with vitamin D deficiency and morbidity among HIV-infected patients enrolled in a large Italian cohort. J Acquir Immune Defic Syndr. 2011;58:163-172.
3. Mehta S, Giovannucci E, Mugusi FM, et al. Vitamin D status of HIV-infected women and its association with HIV disease progression, anemia, and mortality. PLoS One. 2010;5:e8770.
4. Sudfeld CR, Wang M, Aboud S, et al. Vitamin D and HIV progression among Tanzanian adults initiating antiretroviral therapy. PLoS One. 2012;7:e40036.
5. von Essen MR, Kongsbak M, Schjerling P, et al. Vitamin D controls T cell antigen receptor signaling and activation of human T cells. Nat Immunol. 2010;11:344-349.
6. Ansemant T, Mahy S, Piroth C, et al. Severe hypovitaminosis D correlates with increased inflammatory markers in HIV infected patients. BMC Infect Dis. 2013;13:7.
7. Rutstein R, Downes A, Zemel B, et al. Vitamin D status in children and young adults with perinatally acquired HIV infection. Clin Nutr. 2011;30:624-628.
8. Haug C, Müller F, Aukrust P, et al. Subnormal serum concentration of 1,25-vitamin D in human immunodeficiency virus infection: correlation with degree of immune deficiency and survival. J Infect Dis. 1994;169:889-893.
9. Bang UC, Brandt L, Benfield T, et al. Changes in 1,25-dihydroxyvitamin D and 25-hydroxyvitamin D are associated with maturation of regulatory T lymphocytes in patients with chronic pancreatitis: a randomized controlled trial. Pancreas. 2012;41:1213-1218.
10. Kim JH, Gandhi V, Psevdos G Jr, et al. Evaluation of vitamin D levels among HIV-infected patients in New York City. AIDS Res Hum Retroviruses. 2012;28:235-241.
11. Bearden A, Abad C, Gangnon R, et al. Cross-sectional study of vitamin D levels, immunologic and virologic outcomes in HIV-infected adults. J Clin Endocrinol Metab. 2013;98:1726-1733.
12. Dougherty K, Schall J, Zemel B et al. Safety and efficacy of high dose daily vitamin D3 supplementation in children and young adults infected with HIV. J Pediatr Infect Dis Soc. [published online ahead of print July 1, 2014]. DOI: 10,1093/jpids/piu012.
13. Irlam JH, Visser MM, Rollins NN, Siegfried N. Micronutrient supplementation in children and adults with HIV infection. Cochrane Database Syst Rev. 2010;CD003650.
14. Irlam JH, Siegfried N, Visser ME, et al. Micronutrient supplementation for children with HIV infection. Cochrane Database Syst Rev. 2013;10:CD010666.
15. Arpadi SM, McMahon D, Abrams EJ, et al. Effect of bimonthly supplementation with oral cholecalciferol on serum 25-hydroxyvitamin D concentrations in HIV-infected children and adolescents. Pediatrics. 2009;123: e121-e126.
16. Havens PL, Mulligan K, Hazra R, et al Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) 063 Study Team. Serum 25-hydroxyvitamin D response to vitamin D3 supplementation 50,000 IU monthly in youth with HIV-1 infection. J Clin Endocrinol Metab. 2012;97:4004-4013.
17. Holick MF. Vitamin D status: measurement, interpretation, and clinical application. Ann Epidemiol. 2009;19:73-78.
18. Heaney RP. Vitamin D: criteria for safety and efficacy. Nutr Rev. 2008;66(10 suppl 2):S178-S181.
19. Heaney RP, Davies KM, Chen TC, et al. Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol. Am J Clin Nutr. 2003;77:204-210.
20. Ng K, Scott JB, Drake BF, et al. Dose response to vitamin D supplementation in African Americans: results of a 4-arm, randomized, placebo-controlled trial. Am J Clin Nutr. 2014;99:587-598.
21. Powe CE, Ricciardi C, Berg AH, et al. Vitamin D-binding protein modifies the vitamin D-bone mineral density relationship. J Bone Miner Res. 2011;26:1609-1616.
22. Flynn PM, Rudy BJ, Douglas SD, et al Pediatric AIDS Clinical Trial Group 381 Study Team. Virologic and immunologic outcomes after 24 weeks in HIV type 1-infected adolescents receiving highly active antiretroviral therapy. J Infect Dis. 2004;190:271-279.
23. Starr SE, Sarr M, Campbell DE, et al. Increased proliferation within T lymphocyte subsets of HIV-infected adolescents. AIDS Res Hum Retroviruses. 2002;18:1301-1310.
24. Groleau V, Herold RA, Schall JI, et al. Blood lead concentration is not altered by high-dose vitamin D supplementation in children and young adults with HIV. J Pediatr Gastroenterol Nutr. 2013;56:316-319.
25. Kuczmarski RJ, Ogden CL, Grummer-Strawn LM, et al. CDC Growth Charts: United States. Advance Data from Vital and Health Statistics; No. 314 Ed. Hyattsville, MD: National Center for Health Statistics; 2000;1-28.
26. Morris NM, Udry JR. Validation of a self-administered instrument to assess stage of adolescent development. J Youth Adolesc. 1980;9:271-280.
27. IOM (Institute of Medicine). Dietary Reference Intakes for Calcium and Vitamin D. Washington, DC: IOM; 2011.
28. Aloia JF, Patel M, Dimaano R, et al. Vitamin D intake to attain a desired serum 25-hydroxyvitamin D concentration. Am J Clin Nutr. 2008;87: 1952-1958.
29. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of Antiretroviral Agents in HIV-1-infected Adults and Adolescents. Department of Health and Human Services. Available at: http://aidsinfo.nih.gov/guidelines/html/i/adult-and-adolescent-treatmentguidelines/0/. Accessed August 26, 2014.
30. Stephensen CB, Marquis GS, Kruzich LA, et al. Vitamin D status in adolescents and young adults with HIV infection. Am J Clin Nutr. 2006;83: 1135-1141.
31. Eckard AR, Judd SE, Ziegler TR, et al. Risk factors for vitamin D deficiency and relationship with cardiac biomarkers, inflammation and immune restoration in HIV-infected youth. Antivir Ther. 2012;17:1069-1078.
32. Kakalia S, Sochett EB, Stephens D, et al. Vitamin D supplementation and CD4 count in children infected with human immunodeficiency virus. J Pediatr. 2011;159:951-957.
33. Giacomet V, Vigano A, Manfredini V, et al. Cholecalciferol supplementation in HIV-infected youth with vitamin D insufficiency: effects on vitamin D status and T-cell phenotype: a randomized controlled trial. HIV Clin Trials. 2013;14:51-60.
34. Meyzer C, Frange P, Chappuy H et al. Vitamin D Deficiency and Insufficiency in HIV Infected Children and Young Adults. Pediatr Infect Dis J. 2013;32:1240-1244.
35. Arpadi SM, McMahon DJ, Abrams EJ, et al. Effect of supplementation with cholecalciferol and calcium on 2-y bone mass accrual in HIV-infected children and adolescents: a randomized clinical trial. Am J Clin Nutr. 2012;95:678-685.
36. Steenhoff AP, Redwood A, Pettifor JM, et al. Vitamin D status in HIV-infected patients with and without tuberculosis: a pilot study. J Acquir Immune Defic Syndr. 2012;61:e21-e23.
37. Saintonge S, Bang H, Gerber LM. Implications of a new definition of vitamin D deficiency in a multiracial us adolescent population: the National Health and Nutrition Examination Survey III. Pediatrics. 2009;123:797-803.
38. Hathcock JN, Shao A, Vieth R, et al. Risk assessment for vitamin D. Am J Clin Nutr. 2007;85:6-18.
39. Vieth R. Vitamin D toxicity, policy and science. J Bone Miner Res. 2007;22:V64-V68.
40. Vieth R. Implications for 25-hydroxyvitamin D testing of public health policies about the benefits and risks of vitamin D fortification and supplementation. Scand J Clin Lab Invest Suppl. 2012;243:144-153.
41. Longenecker CT, Hileman CO, Carman TL, et al. Vitamin D supplementation and endothelial function in vitamin D deficient HIV-infected patients: a randomized placebo-controlled trial. Antivir Ther. 2012;17:613-621.
42. Van Den Bout-Van Den Beukel CJ, Fievez L, Michels M, et al. Vitamin D deficiency among HIV type 1-infected individuals in the Netherlands: effects of antiretroviral therapy. AIDS Res Hum Retroviruses. 2008;24:1375-1382.
43. Havens PL, Stephensen CB, Hazra R, et al; Adolescent Medicine Trials Network (ATN) for HIV/AIDS Interventions 063 study team. Vitamin D3 decreases parathyroid hormone in HIV-infected youth being treated with tenofovir: a randomized, placebo-controlled trial. Clin Infect Dis. 2012;54:1013-1025.
44. Rosenvinge MM, Gedela K, Copas AJ, et al. Tenofovir-linked hyperparathyroidism is independently associated with the presence of vitamin D deficiency. J Acquir Immune Defic Syndr. 2010;54:496-499.
45. Tafazoli A, Khalili H. Vitamin D and HIV infection: a review of the clinical evidence. Future Virol. 2013;8:589-606.
46. Chun RF, Peercy BE, Orwoll ES, et al. Vitamin D and DBP: The free hormone hypothesis revisited. J Steroid Biochem Mol Biol. 2013;144PA:132-137.
47. Denburg MR, Kalkwarf HJ, de Boer IH, et al. Vitamin D bioavailability and catabolism in pediatric chronic kidney disease. Pediatr Nephrol. 2013;28:1843-1853.
48. Powe CE, Evans MK, Wenger J, et al. Vitamin D-binding protein and vitamin D status of black Americans and white Americans. N Engl J Med. 2013;369:1991-2000.
49. Girasole G, Wang JM, Pedrazzoni M, et al. Augmentation of monocyte chemotaxis by 1 alpha,25-dihydroxyvitamin D3. Stimulation of defective migration of AIDS patients. J Immunol. 1990;145:2459-2464.
50. Villamor E. A potential role for vitamin D on HIV infection? Nutr Rev. 2006;64(5 pt 1):226-233.
51. Haug CJ, Müller F, Aukrust P, et al. Different effect of 1,25-dihydroxyvitamin D3 on replication of Mycobacterium avium in monocyte-derived macrophages from human immunodeficiency virus-infected subjects and healthy controls. Immunol Lett. 1998;63:107-112.
52. Adams JS, Hewison M. Unexpected actions of vitamin D: new perspectives on the regulation of innate and adaptive immunity. Nat Clin Pract Endocrinol Metab. 2008;4:80-90.
53. Haug CJ, Müller F, Rollag H, et al. The effect of 1,25-vitamin D3 on maturation of monocytes from HIV-infected patients varies with degree of immunodeficiency. APMIS. 1996;104:539-548.
54. Teichmann J, Stephan E, Discher T, et al. Changes in calciotropic hormones and biochemical markers of bone metabolism in patients with human immunodeficiency virus infection. Metabolism. 2000;49:1134-1139.
55. Teichmann J, Stephan E, Lange U, et al. Osteopenia in HIV-infected women prior to highly active antiretroviral therapy. J Infect. 2003;46:221-227.
56. Bang U, Kolte L, Hitz M, et al. Correlation of increases in 1,25-dihydroxyvitamin D during vitamin D therapy with activation of CD4+ T lymphocytes in HIV-1-infected males. HIV Clin Trials. 2012;13:162-170.
57. Borkowsky W, Stanley K, Douglas SD, et al. Immunologic response to combination nucleoside analogue plus protease inhibitor therapy in stable antiretroviral therapy-experienced human immunodeficiency virus-infected children. J Infect Dis. 2000;182:96-103.
58. Kestens L, Vanham G, Gigase P, et al. Expression of activation antigens, HLA-DR and CD38, on CD8 lymphocytes during HIV-1 infection. AIDS. 1992;6:793-797.
59. Ironson G, Balbin E, Solomon G, et al. Relative preservation of natural killer cell cytotoxicity and number in healthy AIDS patients with low CD4 cell counts. AIDS. 2001;15:2065-2073.
60. Cozzolino M, Vidal M, Arcidiacono MV, et al. HIV-protease inhibitors impair vitamin D bioactivation to 1,25-dihydroxyvitamin D. AIDS. 2003;17:513-520.
61. Drain PK, Kupka R, Mugusi F, et al. Micronutrients in HIV-positive persons receiving highly active antiretroviral therapy. Am J Clin Nutr. 2007;85:333-345.
62. Madeddu G, Spanu A, Solinas P, et al. Bone mass loss and vitamin D metabolism impairment in HIV patients receiving highly active antiretroviral therapy. Q J Nucl Med Mol Imaging. 2004;48:39-48.
63. Welz T, Childs K, Ibrahim F, et al. Efavirenz is associated with severe vitamin D deficiency and increased alkaline phosphatase. AIDS. 2010;24: 1923-1928.
64. Pasquet A, Viget N, Ajana F, et al. Vitamin D deficiency in HIV-infected patients: associated with non-nucleoside reverse transcriptase inhibitor or efavirenz use? AIDS. 2011;25:873-874.
65. Conesa-Botella A, Florence E, Lynen L, et al. Decrease of vitamin D concentration in patients with HIV infection on a non nucleoside reverse transcriptase inhibitor-containing regimen. AIDS Res Ther. 2010;7:40.
66. Mueller NJ, Fux CA, Ledergerber B, et al Swiss HIV Cohort Study. High prevalence of severe vitamin D deficiency in combined antiretroviral therapy-naive and successfully treated Swiss HIV patients. AIDS. 2010;24:1127-1134.
67. Baum MK, Campa A, Lai S, et al. Effect of micronutrient supplementation on disease progression in asymptomatic, antiretroviral-naive, HIV-infected adults in Botswana: a randomized clinical trial. JAMA. 2013;310:2154-2163.